Key Dates

Related Announcements

• March 15, 2023 - Notice of Special Interest (NOSI): Availability of Administrative Supplements to IDeA Awards to Fund Team Science Development Projects. See Notice NOT-GM-23-034.
• October 9, 2020 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional). See NOFO PA-20-272.

Issued by

National Institute of General Medical Sciences (NIGMS)

Purpose

The National Institute of General Medical Sciences (NIGMS) announces the availability of funds for administrative supplements to current recipients of the Institutional Development Award (IDeA) program including Centers of Biomedical Research Excellence (COBRE) (P20, P30), IDeA Networks of Biomedical Research Excellence (INBRE) (P20), and IDeA Networks for Clinical and Translational Research (IDeA-CTR) (U54) awards. 

This NOSI aims to support the development of team science projects comprised of two to four investigators from IDeA states who offer different perspectives and expertise to address complex basic, behavioral, clinical and/or translational research questions with complementary approaches. These research questions should not duplicate those currently being pursued by the investigators or by the parent awards and should clearly benefit from the collaborative efforts.

Examples of qualifying team science research questions for this NOSI include but are not limited to:

• applying data science approaches and/or cutting-edge technologies to investigate a fundamental biological or disease-related process, and
• for parent grants that involve human subjects, studies that extend laboratory research to clinical or behavioral investigations, and clinical studies that address health conditions prevalent in IDeA states.

Applicants should propose innovative ideas and rigorous study design. Preliminary results are not required. It is expected that these supplements will facilitate the development of synergistic teams and generate preliminary data that lead to joint applications to collaborative funding opportunities.  

Program Directors/Principal Investigators (PD/PI(s)) and Co-Project Leaders

• The PD/PI of an application to this NOSI must be one of the PDs/PIs of an active COBRE, INBRE, or IDeA-CTR award. 
• A PD/PI of an active IDeA award, including one in no cost extension, may not serve as a co-Project Leader on any application to this NOSI.
• At least one co-Project Leader must be either a current or former Project Leader (includes leads of Pilot and Supplement Projects) or a current or former lead (director) of a core other than the Administrative Core who has been supported in their role during the current 5-year project period of the submitting IDeA award.  
• At least one co-Project Leader must be an independent investigator from an IDeA state organization who has not been supported by the submitting IDeA award during its current 5-year period of support.
• Teams of co-Project Leaders who have been supported by different parent IDeA awards and/or are from different organizations or IDeA states are encouraged.
• Co-Project Leaders supported by supplement awards under this NOSI remain eligible to receive simultaneous research support as Project Leaders from a parent IDeA award, as allowable.

Application and Submission Information

Applications for this initiative must be submitted to PA-20-272, “Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)” or its subsequent reissuance by the application due date.

All instructions in the SF424 (R&R) Application Guide and PA-20-272 must be followed, with the following additions:

• Application Due Date – March 1, 2024, by 5:00 PM local time of the applicant organization.
• For funding consideration, applicants must include “NOT-GM-24-001” (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.
• Only one application per parent grant may be submitted in response to this NOSI.
• The title of the supplement must be identical to the title of the parent award.
• The terms and conditions of the parent IDeA award apply, including that the proposed research must not constitute a change in scope of the parent award.
• The supplement application can only propose work with vertebrate animals or human subjects if the parent grant has already been approved to conduct such research.
• The parent award must be active when the supplement application is submitted (e.g., within the originally reviewed and approved project period and not currently in a no-cost extension).
• Budget:
  • Requests may be for a maximum of one year of support. The duration of the proposed project may not extend beyond the end date of the parent grant’s project period.
  • The total budget request for all investigators in this collaborative project may not exceed that of the parent award, exclusive of Facilities and Administrative costs on subcontracts. All requests must be appropriate for the proposed research and efforts.
  • Up to $600,000 in direct costs may be requested to support all co-Project Leaders combined, and support for an individual co-Project Leader may not exceed $200,000 in direct costs for their portion of the research.
  • Up to $60,000 in direct costs may be requested for the PD/PI and supporting staff’s efforts in managing the award.
  • Supplement awards may provide support above the established program budget limits for the parent grant award.
  • As part of the budget justification, a statement regarding the plans for expenditure of currently available unobligated grant funds of the parent award should be included.
• The Research Plan Section should include the following elements:
  • The Project Summary is limited to 1 page and should summarize the goal of the parent award, describe the research question to be addressed by the supplement award, and explain how it will benefit from the team science effort. 
  • The Specific Aims are limited to 1 page and should include a descriptive title for the team science project.
  • The Research Strategy section must include an Overall Approach section (limited to 3 pages) and two to four Research Contribution sections, each written by one of the co-Project Leaders (each limited to 2 pages).
    • The Overall Approach section should summarize the significance of the proposed research including the critical gap(s) in science that will be addressed, and include a description of the current research program, area of expertise and proposed research of each co-Project Leader.  The status of each co-Project Leader as being supported or not supported by the parent award should be included. This section should also address the feasibility of completing the aims within the proposed one-year project period, and describe the anticipated synergy of the collaboration and how the outcomes will deepen collaboration for future joint grant submissions.
    • Each Research Contribution section should describe the approaches, methodology, and analyses to be used to accomplish the Specific Aim(s) or sub-aim(s) directed by the co-Project Leader. Anticipated obstacles and plans to mitigate them should be discussed.
  • If the proposed research involves vertebrate animals, human biospecimens or data, and/or human subjects research, include the necessary documentation as described in the parent IDeA Notice of Funding Opportunity. 

Reporting

Award recipients will be required to include progress on the supplement in the parent award Research Performance Progress Report (RPPR). The progress report should include information on scientific accomplishments, publications, and collaborative grant applications submitted. The information will be used to assess the effectiveness of the supplement award. 

Applicants are strongly encouraged to notify the contact listed below when a request has been submitted in response to this NOSI in order to facilitate efficient processing of the request.

Inquiries

Please direct all inquiries to:

Wuhong Pei, PhD
National Institute of General Medical Sciences (NIGMS)
Email: [email protected]